Stifel lowered the firm’s price target on Amwell (AMWL) to $6 from $8 and keeps a Hold rating on the shares. While the company’s execution on cost takeout and the DHA contract launch have been positive, visibility remains limited on several fronts, the analyst tells investors in a post-earnings note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMWL:
- American Well: Balancing Cost Reductions and Revenue Challenges Amidst Transformation
- Amwell Reports Strong Q3 2025 Financial Performance
- American Well: Hold Rating Amid Revenue Concerns and Strategic Initiatives
- Amwell lowers top-end of FY25 revenue view to $245M-$248M from $245M-$250M
- Amwell reports Q3 EPS ($2.00), consensus ($1.46)